LFB

SpikImm Announces the Signature of an Exclusive License Option and Collaboration Agreement With SATT Conectus for the Development of a Prophylactic Treatment Against the BK Virus, Causing Severe Complications in Transplant Patients

Retrieved on: 
Tuesday, April 16, 2024
COVID-19, Research, Infectious Diseases, Clinical Trials, Biotechnology, Other Health, Health, Other Science, Science, Infection, Antibody, University, Bone marrow, Pasteur Institute, BK, Hospital, Kidney, Risk, SARS-CoV-2, Viral, Heart, MD, Doctor of Philosophy, Vaccine, Life, BK virus, European, Disease, System, Transplant, ANR, Patient, Doctor of Pharmacy, CHU, Hemorrhagic cystitis, LFB, Immunodeficiency, BKV, Bladder cancer, University of Strasbourg

This agreement reinforces SpikImm's portfolio and expertise for the prophylactic treatment of viral infections in immunocompromised patients.

Key Points: 
  • This agreement reinforces SpikImm's portfolio and expertise for the prophylactic treatment of viral infections in immunocompromised patients.
  • BK virus (BKV) infects most individuals early in life and typically remains latent in the body without causing disease.
  • However, under immunosuppressive treatment, in particular in transplant patients, BKV can reactivate and replicate in the urinary tract, leading to potentially serious complications.
  • SpikImm and SATT Conectus today announced the signature of an exclusive option agreement for the anti-BKV monoclonal antibodies.

World Hemophilia Day 2024"Equitable access for all: recognizing all bleeding disorders"

Retrieved on: 
Wednesday, April 17, 2024
Haemophilia, World government, Bleeding, Woman, CSL Behring, City, WFH, NMO, Male, Parent, Friends, World Federation of Hemophilia, Novo Nordisk, Treatment, Bayer, LFB, Diagnosis, All, Coagulopathy, VWD, Therapy, Sanofi, Birth control

MONTREAL, April 17, 2024 /PRNewswire/ -- On April 17, 2024, the global bleeding disorders community will come together to celebrate World Hemophilia Day.

Key Points: 
  • MONTREAL, April 17, 2024 /PRNewswire/ -- On April 17, 2024, the global bleeding disorders community will come together to celebrate World Hemophilia Day.
  • The theme of the event this year is "Equitable access for all: recognizing all bleeding disorders".
  • The World Federation of Hemophilia (WFH) vision of Treatment for All is for a world where all people with inherited bleeding disorders have access to care, regardless of their type of bleeding disorder, gender, age, or where they live.
  • This April, let's celebrate our community and continue working towards a world where everyone—with hemophilia A or B, von Willebrand disease (VWD) or any other bleeding disorder—has access to diagnosis, treatment, and comprehensive care.

World Hemophilia Day 2024"Equitable access for all: recognizing all bleeding disorders"

Retrieved on: 
Wednesday, April 17, 2024
Haemophilia, World government, Bleeding, Woman, CSL Behring, City, WFH, NMO, Male, Parent, Friends, World Federation of Hemophilia, Novo Nordisk, Treatment, Bayer, LFB, Diagnosis, All, Coagulopathy, VWD, Therapy, Sanofi, Birth control

MONTREAL, April 17, 2024 /PRNewswire/ - On April 17, 2024, the global bleeding disorders community will come together to celebrate World Hemophilia Day.

Key Points: 
  • MONTREAL, April 17, 2024 /PRNewswire/ - On April 17, 2024, the global bleeding disorders community will come together to celebrate World Hemophilia Day.
  • The theme of the event this year is "Equitable access for all: recognizing all bleeding disorders".
  • The World Federation of Hemophilia (WFH) vision of Treatment for All is for a world where all people with inherited bleeding disorders have access to care, regardless of their type of bleeding disorder, gender, age, or where they live.
  • This April, let's celebrate our community and continue working towards a world where everyone—with hemophilia A or B, von Willebrand disease (VWD) or any other bleeding disorder—has access to diagnosis, treatment, and comprehensive care.

Global Blood & Plasma Components Market Outlook 2023-2027 with Revenue Shares by Product, Application, End-user and Company - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 29, 2023
Health, Other Health, Emergent BioSolutions, Albumin, Bleeding, Prevalence, Accident, Neurogenesis, Antibody, RFID, Takeda Pharmaceutical Company, New York Blood Center, Cancer, Ageing, Emergent, Octapharma, Research, Coagulopathy, LFB, Organization, Plasma, Death, CSL Limited, Hemoglobinopathy, Von Willebrand disease, Patient, Blood, Hematology, Growth, Conditional sentence, WHO, Blood volume, Haemophilia A, Trauma, Blood product, Pharmaceutical industry

The Global Blood & Plasma Components Market Outlook 2023-2027 report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The Global Blood & Plasma Components Market Outlook 2023-2027 report has been added to ResearchAndMarkets.com's offering.
  • The global blood & plasma components market is poised for impressive growth within the forecast period of 2023-2027.
  • The increasing occurrence of these situations significantly bolsters the global blood and plasma component market.
  • The global blood & plasma components market is categorized based on products, applications, end-users, and companies.

GTT Unveils New Brand Focused on “Making Exceptional Possible” for Its Customers

Retrieved on: 
Monday, January 16, 2023
GTT, GTT Communications, Communication, European Space Agency, SD, Intelligence, Automation, Research, IDC, LFB, Risk management

With the tagline “Making exceptional possible,” GTT’s new identity strongly conveys its commitment to helping customers thrive in a world that has become dependent on digital business, enabled by the company’s leading portfolio of managed services and global support.

Key Points: 
  • With the tagline “Making exceptional possible,” GTT’s new identity strongly conveys its commitment to helping customers thrive in a world that has become dependent on digital business, enabled by the company’s leading portfolio of managed services and global support.
  • “Our new tagline, ‘Making exceptional possible,’ places our focus firmly on our customers and providing the secure network solutions and support they need to thrive.
  • This commitment is at the center of everything we do.”
    The new brand recognizes the company’s expertise in supporting customers with leading SD-WAN, networking and security solutions.
  • It reflects GTT’s expertise and collaborative approach that helps customers realize the full potential of their network and security solutions.

Plasma Fractionation Global Market Report 2022: Ukraine-Russia War Impact

Retrieved on: 
Friday, December 9, 2022
HYCON, Virus, Disease, CSL Limited, Shire (pharmaceutical company), Immune system, Antibody, Conditional sentence, Plasma, Glycoprotein, Takeda Pharmaceutical Company, Chronic condition, Hematology, Patient, Prevalence, Cancer, Immunodeficiency, Critical care, Bio Products Laboratory, Hospital, Takeda, Coagulopathy, Degenerative disease, LFB, Neurology, Diabetes, World Health Organization, Quality of life, Green Cross, COVID-19, Rheumatology, Inflammation, Growth, Octapharma, Death, Protease, B cell, Organization, Acquisition, Baxter International, Pharmaceutical industry, Lithium, Fine chemical, Blood product, Renewable energy, Takeda Oncology

The plasma fractionation market is expected to grow to $35.67 billion in 2026 at a compound annual growth rate (CAGR) of 8.26%.

Key Points: 
  • The plasma fractionation market is expected to grow to $35.67 billion in 2026 at a compound annual growth rate (CAGR) of 8.26%.
  • The plasma fractionation market consists of sales of plasma fractionation by entities (organizations, sole traders, and partnerships) that are used in the manufacture of essential pharmaceutical products that are used to treat immune deficiencies or bleeding disorders.Plasma fractionation refers to the process of separating the various components of blood plasma.
  • The regions covered in plasma fractionation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
  • The plasma fractionation market research report is one of a series of new reports that provides plasma fractionation market statistics, including plasma fractionation industry global market size, regional shares, competitors with an plasma fractionation market share, detailed plasma fractionation market segments, market trends and opportunities, and any further data you may need to thrive in the plasma fractionation industry.

Global Blood Plasma Market Report 2022 to 2030: Featuring Bayer, Biotest, CSL, Fusion Health and Octa Pharma Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 3, 2022
Biotechnology, Pharmaceutical, Health, Blood plasma, COVID-19, Awareness, Growth, LFB, Element, Infection, Industry, Immunodeficiency, Population, WHO, Antibody, CSL Limited, Revenue, Organization, Bayer, Degenerative disease, PID, Grifols, Patient, Medical device, Agriculture, Pharmaceutical industry, Takeda

The rise in chronic conditions and increasing demand for immunoglobulin drive the development of the industry.

Key Points: 
  • The rise in chronic conditions and increasing demand for immunoglobulin drive the development of the industry.
  • The expansion in the maturing population around the world might trigger a spike in infections that require blood treatment.
  • Market participants such as Biotest, CSL Limited, Grifols, S.A, Kedrion Biopharma, LFB S.A, Octa Pharma, Bayer AG, Sanofi, Fusion Health, and Takeda are some of the key players operating in the market.
  • The publisher has segmented the blood plasma market report based on type, application, end-use, and region:
    Blood Plasma, Type Outlook (Revenue - USD Billion, 2018 - 2030)

Denis DELVAL is appointed President of the Ethypharm Group

Retrieved on: 
Monday, October 10, 2022
LinkedIn, Bayer, Supervisory board, INSEAD, ESSEC, Senior, ALK, Marketing, LFB, Group, CEO, CNS, Central nervous system, Pharmaceutical industry, Pharmacy

SAINT-CLOUD, France, Oct. 10, 2022 /PRNewswire/ -- The Supervisory Board appointed Denis DELVAL as CEO of the Ethypharm Group. 

Key Points: 
  • SAINT-CLOUD, France, Oct. 10, 2022 /PRNewswire/ -- The Supervisory Board appointed Denis DELVAL as CEO of the Ethypharm Group.
  • In 2017, he was appointed President of LFB, a biopharmaceutical group that develops, manufactures and markets medicinal products derived from living matter.
  • I look forward to mobilising energies and continuing the development of the Group", Denis DELVAL announced.
  • Ethypharm is a European pharmaceutical company specialising in two areas: the Central Nervous System and Hospital Injectable Medicines.

LFB Plasma Joins Plasma Protein Therapeutics Association (PPTA)

Retrieved on: 
Friday, September 9, 2022
Alternative Medicine, Health, Infectious Diseases, Health Technology, Other Health, Pharmaceutical, CEO, Safety, CO, AL, Collection, SVP, PPTA, Blood, LFB, Family, Patient, Blood product, Medical device, Plasma

LFB Plasma, a US-based plasma collection company and subsidiary of the LFB Group, a leading European company providing plasma-derived products to healthcare professionals, announces joining the Plasma Protein Therapeutics Association (PPTA).

Key Points: 
  • LFB Plasma, a US-based plasma collection company and subsidiary of the LFB Group, a leading European company providing plasma-derived products to healthcare professionals, announces joining the Plasma Protein Therapeutics Association (PPTA).
  • LFB Plasma operates plasma collection centers in Greenacres and Fort Pierce, FL, High Point, NC, and Florence, SC, and will soon open centers in Pueblo, CO and Anniston, AL.
  • Plasma Protein Therapeutics Association (PPTA) is a global organization that represents manufacturers of plasma-derived and recombinant analog therapies, collectively known as plasma protein therapies and the collectors of source plasma used for fractionation.
  • Since opening, LFB Plasma expanded into three states and has plans to open plasma collection centers in two more states by mid-2023.

LFB Announces the Approval of CEVENFACTA® (eptacog beta) in the European Union

Retrieved on: 
Monday, July 25, 2022
Science, Biotechnology, Research, Pharmaceutical, Managed Care, Health, Genetics, Clinical Trials, Anticoagulant, LFB, Bleeding, VIII, BU, EMA, European Medicines Agency, Patient, Pharmaceutical industry

LFB today announced that the European Medicines Agency (EMA) has granted on July 15th a Marketing Authorisation for CEVENFACTA (eptacog beta), as the first new bypassing agent in over 20 years.

Key Points: 
  • LFB today announced that the European Medicines Agency (EMA) has granted on July 15th a Marketing Authorisation for CEVENFACTA (eptacog beta), as the first new bypassing agent in over 20 years.
  • Denis Delval, LFBs Chairman and Chief Executive Officer, stated: We are very pleased with the approval of CEVENFACTA by the EMA, which provides a new treatment option for haemophilia patients with inhibitors in the European Union.
  • This approval is a validation of our innovative LFB technology and the acknowledgement of LFBs deep commitment to patients.
  • The approval of CEVENFACTA was based on data from the phase III clinical trials, PERSEPT 1 and PERSEPT 3.